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Successful immunosuppressive
treatment and long-term follow-
up of anti-Ri-associated
paraneoplastic myelitis
Antineuronal antibody-associated paraneo-
plastic neurological syndromes (PaNSs)
result from tumour-stimulated autoimmune
attacks against components of the nervous
system. The rare antineuronal antibody anti-
Ri (ANNA-2) was initially thought to be
closely associated with paraneoplastic
opsoclonus–myoclonus syndrome. Recently,
however, it has been found in several other
PaNSs.1 First-line treatment in PaNSs is
removal of the underlying tumour. Second-
line treatment is immunosuppression, which,
although extensively used, especially when
no tumour is detected, is often ineffective.
Often, patients die from relentlessly progress-
ive PaNS rather than the underlying neo-
plasm.2 Here, we report the 2-year follow-up
of an anti-Ri-positive steroid-responsive
myeloneuropathy. No tumour was detected.
Immunosuppressive treatment was tailored
on the basis of clinical relapses, inflammatory
changes in cerebrospinal fluid (CSF) and
somatosensory evoked potentials (SEPs).
A 65-year-old woman, a retired adminis-
trator, was referred to our department with a
10-month history of progressive gait difficult-
ies and ascending sensory loss in her legs,
eventually having become wheelchair bound.
Her medical history was unremarkable apart
from enlarged axillary lymph nodes that were
excised 9 months earlier. Histological exam-
ination showed only inflammatory changes.
She had received hormone replacement
therapy for 11 years. She never smoked.
On neurological examination, deep tendon
reflexes were absent. She had spastic para-
paresis with bilateral extensor plantar
responses. Bilateral hypaesthesia for light
touch up to the knees and diminished
vibration sense were observed distally in her
legs. Magnetic resonance imaging (MRI)
showed symmetrical T2-hyperintense multi-
segmental (C6–TH3/TH8–TH12) cervicothor-
acal lesions of the spinal cord, with
gadolinium enhancement restricted to the
lateral parts (fig 1A). Cerebral MRI showed
only minor microangiopathic changes. Nerve
conduction studies showed normal tibial
nerve conduction velocities (NCV), slightly
reduced right median NCV (forearm 41 m/s,
normal .41 m/s) and moderately reduced
sural NCV (32 m/s, normal .40 m/s). Right
median (32 ms, normal 28 ms) and tibial
(61 ms, normal 52 ms) nerve F-wave laten-
cies were prolonged, in keeping with poly-
neuropathy. SEPs after median nerve
stimulation were normal; tibial SEP was
absent bilaterally. An examination of the
CSF showed pleocytosis (80% lymphocytes)
and disturbed blood–CSF barrier (fig 1B).
Microbiological serology of serum and CSF
showed no evidence of acute infection.
Routine laboratory tests were normal.
Rheumatoid factor, anti-neutrophil and
anti-nuclear autoantibodies were not found.
Immunofluorescence screening for onco-
neural antibodies using monkey cerebellum,
jejunum and peripheral nerve showed high-
titre antineuronal nuclear antibodies in
serum (1:1920) and CSF, with a pattern
suggestive of anti-Ri antibodies. Subsequent
immunoblots with recombinant targets of
anti-Ri, anti-Hu, anti-Yo and amphiphysin
antibodies (serum or CSF) confirmed anti-Ri
specificity. In addition, no anti-Ma2, anti-
CRMP5, anti-ANNA-3, anti-PCA2, anti-PCA-
Tr, anti-N or anti-P/Q-calcium channel, anti-
striated muscle or anti-acetylcholine receptor
antibodies were found. Whole-body fluor-
deoxyglucose-positron emission tomography
(FDG-PET) was inconspicuous. Mammo-
graphy showed bilateral mastopathy.
Carcinoembryonic antigen, CA15-3, CA125,
a-fetoprotein, human chorionic gonado-
tropin, and b2-microglobulin were not raised.
The patient was treated with high-dose
steroids for 14 days. In weeks, she regained
the ability of walking with support. Sensory
disturbances improved. Plantar responses
became flexor. A first relapse (relapse 1,
fig 1B) led to a recurring inability to walk
unaided, reappearance of extensor plantar
responses and sensory deficits for all qualities
below TH12. Spinal MRI showed increased
signal abnormalities and gadolinium
enhancement. The number of white blood
cells in the CSF increased and blood–CSF
barrier dysfunction became pronounced.
Although a high-dose steroid treatment and
slow tapering led to improved muscle
strength, reduced sensory disturbances and
increased walking distance as well as normal-
isation of abnormalities of the CSF, in the
ensuing year, two more relapses (fig 1B) were
witnessed, each after tapering steroids below
20 mg prednisolone and associated with the
reappearance of inflammatory CSF (fig 1B).
Increased prednisolone was followed by
clinical improvement and alleviated abnorm-
alities of the CSF. Peroneal SEP latencies
were established as an additional parameter.
Every relapse led to increased residual defi-
cits. Eventually, oligoclonal bands appeared
and remained detectable, mild pleocytosis
persisted and peroneal SEP continued to
deteriorate. As steroidal side effects were no
longer tolerable, monthly cyclophosphamide-
pulsed treatment (650 mg/m2 body surface)
was started. During the following 9 months,
the patient’s condition stabilised and CSF
findings normalised. Six-monthly FDG-PET
did not disclose an underlying malignancy.
Owing to side effects, cyclophosphamide was
eventually discontinued. As azathioprine and
mycophenolate mofetil led to lymphopenia,
intravenous immunoglobulins were started
recently. So far, there has been no relapse.
This patient with anti-Ri antibodies pre-
sented with myeloneuropathy. The non-
classical clinical presentation in combination
with a well-characterised onconeural anti-
body fulfils the criteria of a definite PaNS.3
That no tumour was detected during
36 months is compatible with anti-Ri PaNS.
Only 3% of patients have not developed
cancer within 3 years of follow-up.1 3 The
history of enlarged lymph nodes, oestrogen
treatment and mastopathy is suggestive of
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occult breast cancer; however, histological
examination and PET scanning remained
negative. Another autoimmune non-paraneo-
plastic aetiology of myelitis cannot be
excluded completely. However, no other
autoantibodies—for example, rheumatoid
factor and Sjogren’s syndrome antibodies—
and no systemic manifestations were
detected. Immunofluorescence and recombi-
nant immunoblot confirmed anti-Ri specifi-
city; however, no immunoblot using
cerebellar extracts was carried out.
Therefore, antibodies targeting neuronal pro-
teins other than those tested cannot be
excluded.
Classically, anti-Ri antibodies occur in
PaNS with brain stem dysfunction.1 4 5
Spinal involvement has been described in
12–16% of cases,1 4 5 but, to our knowledge,
this is the first detailed clinical and MRI
description of anti-Ri myelitis with distinct
signal abnormalities not usually encountered
in infectious or other autoimmune myelitis.
Although polyneuropathy was previously
reported in 20% of anti-Ri patients, in almost
half of these cases, additional onconeural
antibodies (anti-Hu, CRMP5/CV2) were also
present.1 As none of these were detected in
this case, it is plausible that myeloneuropathy
was directly related to anti-Ri antibodies.
The long-term treatment of patients with
PaNS without detectable cancer is a challeng-
ing situation. It is often unclear whether
clinical improvements can be attributed to
treatment or simply reflect the natural
clinical course. In the present case, the former
seems more likely. Over 2 years, both starting
and increasing the dosage of steroids was
followed by clinical improvement and
reduced CSF inflammatory changes. As a
corollary, tapering of steroids had an opposite
effect. Of note, steroid responsiveness was
previously reported also in patients with
other anti-Ri positive PANSs.1 4 5
In summary, we report a patient with anti-
Ri positive myeloneuropathy responding to
immunosuppression. White blood cells in the
CSF, CSF–blood-barrier function and pero-
neal SEPs proved to be useful in monitoring
therapeutic responses. This case shows that
long-term treatment of anti-Ri PaNS can be
successful, but still remains a challenge.
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Figure 1 (A) Coronal and sagittal sections of gadolinium-enhanced T1-weighted spinal magnetic resonance image showing symmetrical contrast
enhancement of the lateral aspects of the spinal cord. Asterisk indicates TH12. Dashed line indicates the level of axial section. (B) Clinical course of the
patient starting from May 2003. Continuous line with closed boxes: white blood cells (WBCs (cells/ml), left y axis, normal ,5/ml) in the cerebrospinal
fluid; dashed line with filled circles: QAlb610
3 (albumin ratio serum/cerebral spinal fluid as a parameter of blood brain–barrier function, left y axis,
normal ,8.4); dashed line with filled triangles: differences of left peroneal somatosensory evoked potential (SEP) latencies compared with those from
November 2003 (ms, right y axis). Encircled numbers: numbered clinical relapses; open arrows: cyclophosphamide pulses; line of asterisks: steroid
treatment, roughly corresponding in size of dose; filled line above asterisks: azathioprine treatment.
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